Press Releases

Cyxone signs a UK contract research organization for six-month toxicology studies with Rabeximod

November 21, 2019 13:40 (CET)

Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that the company has signed an agreement with a UK contract research organization (CRO) to conduct the six-month toxicology studies with Rabeximod as required ahead of the Phase IIb study. Preparations for the toxicology studies began immediately with a plan of initiating the studies directly thereafter.

Malin Berthold, Head of Project Management at Cyxone, comments “After thorough evaluation, we were able to decide upon this CRO as our partner of choice for these preclinical studies. The selected CRO has an excellent reputation and we got a great impression of their quality and professionalism from the start. We now look forward to take the next step in the development program for our Phase II candidate Rabeximod.”

The planned clinical phase IIb trial is a multi-center, randomized, double-blind, placebo-controlled, where patients with moderate to severe RA, who have previously been treated with methotrexate with inadequate response, will be treated with Rabeximod for 24 weeks. The aim of the Phase IIb study is to confirm Rabeximod’s therapeutic effect as well as good safety and tolerability. Before patients are treated with Rabeximod for 24 weeks, Cyxone must conduct additional preclinical toxicology studies with the substance to confirm its safety for 24 weeks of treatment. Safety data for 12 weeks of treatment with Rabeximod already exist. The additional toxicology studies are scheduled to be initiated during 2019.


Bert Junno, chairman of Cyxone

Phone: +46 (0) 70 777 22 09


Ola Skanung, CFO and interim CEO

Phone: +46 (0) 705 121 040


About Cyxone

Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA in clinical phase II program. Cyxone’s Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50,

Press release